A novel mouse model of chronic Pseudomonas aeruginosa infection inducing bronchiectasis‐like phenotype Authors: Heng Yang, Yang Liu, Yuqing Wang, Yuhua Wen, Yan Chen, Rui Fan, Jiayan Xu, Shunlian Hu, Hao Qian, Rui Jiang, Weijun Cao, Jinfu Xu Published: 2026 ABSTRACT AbstractBackgroundGiven the need to translate basic research into human therapies, the development and refinement of clinically relevant animal models for bronchiectasis are critically important. To date, there are no well‐established animal models for bronchiectasis. Thus, our aim was to develop a novel animal model that accurately recapitulates bronchiectasis‐like pathologies.MethodsTo address this question, clinical strains of chronic Pseudomonas aeruginosa (CPA) were embedded in agar beads in vitro; then CPA‐loaded agar beads and papain were repeatedly instilled intratracheally in female C57BL/6 J mice. Experimental assessments included micro‐computed tomography (micro‐CT) imaging, histological analysis, immune cell infiltration, cytokines, and lung function parameter measurements to evaluate structural damage, immune responses, and lung function impairments in the mouse model.ResultsIn this mouse model, we observed that lung micro‐CT imaging revealed significant bronchiectasis, with visible airways in the periphery, cylindrical airway expansion, and an airway‐to‐artery ratio > 1. Histopathology highlighted immune cell infiltration around the trachea, including lymphocytes, neutrophils, and monocytes, along with Periodic acid–Schiff staining‐positive hypermucinous secretion. Compared to controls, the bronchiectasis group exhibited elevated pro‐inflammatory cytokines in bronchoalveolar lavage fluid and worse lung function.ConclusionOur study presented a novel mouse model that better replicated the bronchiectasis‐like phenotype than the CPA airway infection model, showing the advantages of the “CPA‐loaded agar beads and papain”–driven approach in optimizing the disease models. The model mimicked the progression of bronchiectasis closely and could be used for studies on disease pathogenesis as well as the evaluation of novel therapies in the near future.Keywords: bronchiectasis, micro‐computed tomography (micro‐CT), mouse model, Pseudomonas aeruginosa INTRODUCTION Noncystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis) is a chronic respiratory disease, causing a considerable burden on the healthcare system. 1 , 2 Pseudomonas aeruginosa represents the predominant micro‐organism cultured from bronchiectatic airways, and its chronic pulmonary infection with P. aeruginosa is linked to higher rates of acute exacerbations as well as greater mortality among individuals with bronchiectasis. 3 , 4 , 5 Knowledge of bronchiectasis pathophysiology has advanced considerably in recent decades, but we still lack a comprehensive understanding of disease progression. 6 Animal models have made significant contributions to elucidating specific mechanisms involved in clinical translational research. 7 Currently, the major obstacle in the study of bronchiectasis is the lack of suitable disease animal models that accurately recapitulate bronchiectasis‐like phenotype. Establishing murine models that accurately replicate chronic P. aeruginosa (CPA) airway infection remains difficult, because introducing free‐living P. aeruginosa into mice typically results in either fulminant sepsis with early mortality or rapid clearance, preventing long‐term colonization. 8 At present there is no established animal model for bronchiectasis, which is usually replaced by using the P. aeruginosa agar‐beads mouse model. However, this chronic infection model primarily focuses on studying the pulmonary inflammation and infection associated with the disease, but it has limitations in replicating typical bronchiectasis‐like radiological features, thereby restricting its application in the study of bronchiectasis‐related pathological mechanisms and therapeutic interventions. 9 , 10 We recently developed an improved mouse infection model for bronchiectasis by focusing primarily on “CPA‐loaded agar beads and papain”–driven approach. In this study, we detailed the methodology for using a combination of CPA strain‐loaded agar beads and papain, which were repeatedly instilled intratracheally in mice. Subsequent evaluations included micro‐computed tomography (micro‐CT) imaging, histological staining, immune cell infiltration, inflammatory cytokine, and lung function assessments in mice. Overall, we established a novel mouse model that mimicked most of the pathological features of human bronchiectasis. The mouse model will assist researchers in addressing fundamental questions regarding the pathogenesis of bronchiectasis and provide technical support for the development of novel therapies for the disease. METHODS Animals Female C57BL/6 J mice (~ 18 g, 6 weeks old) were procured from Shanghai SLRC Laboratory Animal Center. Preparation of CPA‐loaded agar beads It mainly refers to the methodology of Professor Alessandra Bragonzi. 10 Preparation of bacteria Pick a single colony of the CPA strain and inoculate it into a sterile shaking tube containing 4 mL of Luria–Bertani (LB) medium. Culture at 37°C with shaking at 220 rpm for 16–18 h. The CPA strain was originally isolated from a bronchiectasis patient.Transfer 500 μL of the initially shaken bacterial solution into a sterile 50 mL centrifuge tube containing a final volume of 10 mL, and prepare two identical aliquots. Place these mixtures in the incubator at 37°C, with shaking at 220 rpm for 4–5 h. Isolate bacterial cells via centrifugation at 2700 g for 3 min at 4°C, and then reconstitute the bacterial pellet in 1 mL of the supernatant. Preparation of bacteria Pick a single colony of the CPA strain and inoculate it into a sterile shaking tube containing 4 mL of Luria–Bertani (LB) medium. Culture at 37°C with shaking at 220 rpm for 16–18 h. The CPA strain was originally isolated from a bronchiectasis patient.Transfer 500 μL of the initially shaken bacterial solution into a sterile 50 mL centrifuge tube containing a final volume of 10 mL, and prepare two identical aliquots. Place these mixtures in the incubator at 37°C, with shaking at 220 rpm for 4–5 h. Isolate bacterial cells via centrifugation at 2700 g for 3 min at 4°C, and then reconstitute the bacterial pellet in 1 mL of the supernatant. Pick a single colony of the CPA strain and inoculate it into a sterile shaking tube containing 4 mL of Luria–Bertani (LB) medium. Culture at 37°C with shaking at 220 rpm for 16–18 h. The CPA strain was originally isolated from a bronchiectasis patient. Pick a single colony of the CPA strain and inoculate it into a sterile shaking tube containing 4 mL of Luria–Bertani (LB) medium. Culture at 37°C with shaking at 220 rpm for 16–18 h. The CPA strain was originally isolated from a bronchiectasis patient. Transfer 500 μL of the initially shaken bacterial solution into a sterile 50 mL centrifuge tube containing a final volume of 10 mL, and prepare two identical aliquots. Place these mixtures in the incubator at 37°C, with shaking at 220 rpm for 4–5 h. Isolate bacterial cells via centrifugation at 2700 g for 3 min at 4°C, and then reconstitute the bacterial pellet in 1 mL of the supernatant. Transfer 500 μL of the initially shaken bacterial solution into a sterile 50 mL centrifuge tube containing a final volume of 10 mL, and prepare two identical aliquots. Place these mixtures in the incubator at 37°C, with shaking at 220 rpm for 4–5 h. Isolate bacterial cells via centrifugation at 2700 g for 3 min at 4°C, and then reconstitute the bacterial pellet in 1 mL of the supernatant. Embedding bacteria in agar beads Preheat 150 mL of paraffin liquid (MACKLIN, catalog no. C16090135) in a 250 mL Erlenmeyer flask, maintaining a constant temperature of 50°C. Additionally, prepare LB medium containing 1.5% agar at a temperature not exceeding 60°C.Add 1 mL of bacterial suspension to 10 mL of LB medium with 1.5% agar, and mix thoroughly. Transfer the 10 mL LB–CPA strain mixture into paraffin liquid and stir for 6 min at 2000 rpm.Mix slowly for 35 min at 4°C; then allow it to settle on ice for 20 min.Transfer the agar beads into 50 mL centrifuge tubes and centrifuge.Discard the paraffin liquid thoroughly, and add phosphate‐buffered saline (PBS) to resuspend.Discard ~ 10 mL of the oil‐containing PBS, aspirate the solution of smaller beads, and discard the lower layer containing larger particle beads.Filter the beads obtained in the previous step through 200‐ and 100‐μm filters to obtain beads with a diameter of 100–200 μm, with a final volume of ~ 5–15 mL. Finally, perform bacterium colony counting. Embedding bacteria in agar beads Preheat 150 mL of paraffin liquid (MACKLIN, catalog no. C16090135) in a 250 mL Erlenmeyer flask, maintaining a constant temperature of 50°C. Additionally, prepare LB medium containing 1.5% agar at a temperature not exceeding 60°C.Add 1 mL of bacterial suspension to 10 mL of LB medium with 1.5% agar, and mix thoroughly. Transfer the 10 mL LB–CPA strain mixture into paraffin liquid and stir for 6 min at 2000 rpm.Mix slowly for 35 min at 4°C; then allow it to settle on ice for 20 min.Transfer the agar beads into 50 mL centrifuge tubes and centrifuge.Discard the paraffin liquid thoroughly, and add phosphate‐buffered saline (PBS) to resuspend.Discard ~ 10 mL of the oil‐containing PBS, aspirate the solution of smaller beads, and discard the lower layer containing larger particle beads.Filter the beads obtained in the previous step through 200‐ and 100‐μm filters to obtain beads with a diameter of 100–200 μm, with a final volume of ~ 5–15 mL. Finally, perform bacterium colony counting. Preheat 150 mL of paraffin liquid (MACKLIN, catalog no. C16090135) in a 250 mL Erlenmeyer flask, maintaining a constant temperature of 50°C. Additionally, prepare LB medium containing 1.5% agar at a temperature not exceeding 60°C. Preheat 150 mL of paraffin liquid (MACKLIN, catalog no. C16090135) in a 250 mL Erlenmeyer flask, maintaining a constant temperature of 50°C. Additionally, prepare LB medium containing 1.5% agar at a temperature not exceeding 60°C. Add 1 mL of bacterial suspension to 10 mL of LB medium with 1.5% agar, and mix thoroughly. Transfer the 10 mL LB–CPA strain mixture into paraffin liquid and stir for 6 min at 2000 rpm. Add 1 mL of bacterial suspension to 10 mL of LB medium with 1.5% agar, and mix thoroughly. Transfer the 10 mL LB–CPA strain mixture into paraffin liquid and stir for 6 min at 2000 rpm. Mix slowly for 35 min at 4°C; then allow it to settle on ice for 20 min. Mix slowly for 35 min at 4°C; then allow it to settle on ice for 20 min. Transfer the agar beads into 50 mL centrifuge tubes and centrifuge. Transfer the agar beads into 50 mL centrifuge tubes and centrifuge. Discard the paraffin liquid thoroughly, and add phosphate‐buffered saline (PBS) to resuspend. Discard the paraffin liquid thoroughly, and add phosphate‐buffered saline (PBS) to resuspend. Discard ~ 10 mL of the oil‐containing PBS, aspirate the solution of smaller beads, and discard the lower layer containing larger particle beads. Discard ~ 10 mL of the oil‐containing PBS, aspirate the solution of smaller beads, and discard the lower layer containing larger particle beads. Filter the beads obtained in the previous step through 200‐ and 100‐μm filters to obtain beads with a diameter of 100–200 μm, with a final volume of ~ 5–15 mL. Finally, perform bacterium colony counting. Filter the beads obtained in the previous step through 200‐ and 100‐μm filters to obtain beads with a diameter of 100–200 μm, with a final volume of ~ 5–15 mL. Finally, perform bacterium colony counting. Mouse challenge with CPA‐loaded agar beads and papain The animals were anesthetized, and either 30 μL of CPA‐loaded agar beads containing 3 × 106 colony‐forming units or 20 μL of 1.25 mg/mL papain was administered (Sangon Biotech, CAS number 9001‐73‐4). This procedure was carried out once a week for 4 weeks (the framework is shown in Figure 1). The beads were usable up to 1 month at 4°C. During the second, third, and fourth modeling sessions, beads or papain was administered slowly to avoid mouse mortality due to respiratory depression. Schematic diagram of the bronchiectasis mouse model construction. (A) Preparation of chronic Pseudomonas aeruginosa (CPA)‐loaded agar beads. CPA‐loaded agar beads were carefully prepared to achieve persistent infections. (B) Mice were challenged to CPA‐loaded agar beads in combination with papain to produce the bronchiectasis mouse model. (C) The primary experimental methods employed in this study include micro‐computed tomography (micro‐CT), histological analysis, and flow cytometry. Created using BioGDP.com. Micro‐computed tomography The mouse was positioned on the imaging platform carefully. The mouse was placed in a prone position, with its body aligned symmetrically to the axis of the scanner to ensure optimal image acquisition. Scanning procedure: the scan was performed by selecting the appropriate imaging protocol. High‐resolution scanning was performed using the Quantum GX2 CT scanner (PerkinElmer), with parameters set to 90 kV and 88 mA. Histological examination The lobes of the left lung of mice were removed and fixed in 4% formaldehyde. After processing, the tissue samples were stained using two techniques: hematoxylin and eosin (H&E) staining for general histopathological evaluation of lung damage, and Periodic acid–Schiff (PAS) staining for detecting carbohydrate‐rich components, such as PAS‐positive goblet cells or mucus, using a PAS staining kit. 11 Lung function measurement Before initiating the experiment, both the airflow sensor and the amplifier must be calibrated to ensure accurate measurements, following the instrument's guidelines (Harvard Apparatus, catalog no. 55‐7040). The mice were anesthetized to induce controlled sedation. After anesthesia, a tracheostomy was performed using the FTC102 tracheal cannula to establish an airway access. The mice received ventilation at 200 μL of tidal volume and 150 breaths/min. Data recording was initiated to capture the relevant respiratory parameters. Detailed methods for flow cytometry and enzyme‐linked immunosorbent assay (ELISA) are provided in the supplementary material. Statistical analysis We performed statistical analysis using GraphPad Prism, version 9.2. For comparing the two groups, we employed a two‐sided unpaired t‐test when the data followed a normal distribution and a two‐sided Mann–Whitney U‐test for nonnormal data distributions. Statistical significance was established at a threshold of p < 0.05. All measurements were obtained from independent samples, and each experiment was repeated three to five times. RESULTS CPA‐loaded agar bead and papain challenge induces a typical bronchiectasis‐like radiological phenotype in the mouse model In this study, we utilized mouse pulmonary micro‐CT imaging to confirm whether the developed mouse model exhibited bronchiectasis‐like radiological features. The diagnostic criteria were based on the standard radiological definitions used in bronchiectasis adults. 12 , 13 Mice treated with CPA‐loaded agar beads alone for 28 days exhibited only mild peribronchial inflammatory changes in micro‐CT imaging, and no typical bronchiectasis‐like lesions were observed (Figure S1). In contrast, longitudinal micro‐CT imaging of the bronchiectasis model group revealed a time‐dependent progression of bronchiectasis‐like changes (Figure S2A). At day 14 postinduction, only mild airway dilatation was observed, whereas by day 28, the extent of airway dilatation significantly increased (Figure S2B). Particularly, the number of peripheral signet ring signs was substantially higher in the 28‐day group (Figure S2C), indicating more advanced structural distortion of the airways. These findings suggest that airway injury and remodeling peaked at ~ day 28, which was therefore selected as the optimal time point for subsequent experiments. Representative micro‐CT images of the lungs from control mice are shown in Figure 2A, where clear lung markings are observed without any signs of bronchiectasis. In contrast, the bronchiectasis model group exhibited typical bronchiectasis‐like radiological features (Figure 2B,C) First, as shown in Figure 2B, the inner airway‐to‐artery diameter ratio was measured as 0.42 mm/0.23 mm, 0.38 mm/0.24 mm, and 0.39 mm/0.22 mm (Figure 3A) in the bronchiectasis group. All these ratios exceeded 1, meeting the diagnostic criterion for bronchiectasis. Additionally, the typical signet ring sign was evident in all cases, further enhancing diagnostic reliability. Second, a cylindrical pattern of airway expansion was observed in the bronchiectasis model group (Figures 2C and 3B), characterized by the absence of normal tapering in the distal airways, along with increased mucous accumulation (Figure 2C). Third, the CT images revealed visible airways in the periphery of the lungs, a characteristic feature of bronchiectasis (Figures 2C and 3C). These three distinct imaging characteristics provided the strongest basis for the radiological diagnosis of bronchiectasis. CPA (chronic Pseudomonas aeruginosa)–loaded agar beads and papain challenge induces a typical bronchiectasis‐like phenotype in the mouse model. (A) Representative micro‐CT (micro‐computed tomography) images of control mouse lungs. (B) Axial micro‐CT image (left) and schematic drawing (right) showing the dimensions of the trachea and accompanying vessels. (C) The radiological findings included cylindrical airway dilatation, increased visibility of airways in the periphery, and mucous accumulation. Representative micro‐CT (micro‐computed tomography) images highlighting bronchiectasis radiological features in the mouse model. (A) Micro‐CT images showing the signet ring sign, characterized by airway diameters of 0.42 mm/0.23 mm, 0.38 mm/0.24 mm, and 0.39 mm/0.22 mm, respectively. (B) Micro‐CT images demonstrating the absence of normal airway tapering. (C) Micro‐CT images showing the visibility of airways extending to the periphery of lungs. Bronchiectasis‐like pathological phenotypes in mouse model Histological examination of H&E‐stained sections revealed intact lung structure in the control group, with no significant infiltration of inflammatory cells (Figures 4A and S3). Mice in the 14‐day group exhibited variable and relatively mild airway inflammatory changes (Figure S3). The bronchiectasis group exhibited mild pulmonary inflammation, with the inflammatory areas mainly distributed around the airways (Figure 4B,C), which differed from the extensive lung damage typically observed in acute infection and severe lung injury. Moreover, histopathological examination revealed that the trachea was predominantly surrounded by lymphocytes, neutrophils, and monocytes, indicating an active immune response around the airways. Additionally, pronounced infiltration of inflammatory cells was observed around the blood vessels, with lesions predominantly concentrated in the central regions of the lung. Hematoxylin and eosin (H&E) staining of lung tissue sections in the bronchiectasis mouse model. (A) H&E staining of lung tissue from control mice. (B, C) H&E staining of lung tissue from bronchiectasis mice, exhibiting bronchiectasis‐like pathological changes. To further investigate airway mucous secretion, PAS staining was performed, with positive results indicating increased mucous secretion. In our study, we did not observe significant PAS‐positive regions in the normal group (Figure 5A). In contrast, the bronchiectasis group exhibited more PAS‐positive areas, indicating excessive mucous secretion (Figure 5B,C). PAS (Periodic acid–Schiff) staining of lung tissue in the bronchiectasis mouse model. (A) PAS‐stained sections of lung tissue from control mice. (B) PAS‐stained sections from the bronchiectasis mouse model, demonstrating enhanced mucin secretion. (C) Quantification of goblet cell hyperplasia scores (n = 5 per group). Data are presented as mean ± SEM (standard error of the mean). Pulmonary immune response characteristics in the bronchiectasis mouse model To gain a comprehensive understanding of host immune function in bronchiectasis, we conducted fluorescence‐activated cell sorting‐assisted immunophenotyping of CD45+ infiltrates in mouse lungs. In the bronchiectasis mouse model, most myeloid cell populations, such as neutrophils, interstitial macrophages, conventional dendritic cells, and eosinophils, increased (Figures 6A and S5). Additionally, the pulmonary immune response mediated by lymphocytes was characterized by an increase in cytotoxic cell populations, such as natural killer (NK) cells, whereas the proportion of B cells decreased (Figures 6B and S6). Immune cell infiltration in the lungs of the bronchiectasis mouse model. (A) Bar chart showing the percentage of all myeloid cell subsets in both groups of mice. (B) Bar chart showing the percentage of all lymphoid cell subsets in both groups of mice (n = 5 for the control group, n = 7 for the bronchiectasis group). Elevated pro‐inflammatory cytokines and worse lung function were observed in the bronchiectasis mouse model Mice in the bronchiectasis group exhibited a significant reduction in body weight (Figure 7A). Additionally, the bronchiectasis group exhibited a significant increase in airway resistance average (RI, cmH₂O/mL/s) and a significant decrease in the dynamic compliance of the lung (CDyn, mL/cmH₂O) (Figure 7B,C). Furthermore, the bronchiectasis group's bronchoalveolar lavage fluid (BALF) exhibited significantly higher levels of pro‐inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α) and interleukin‐6 (Figure 7D–F). Systemic inflammatory state and lung function changes in the bronchiectasis mouse model. (A) Comparison of body weight between control and bronchiectasis mouse model groups. (B, C) Comparison of airway resistance and lung compliance between the two groups of mice. (D–F) Difference in inflammatory cytokine levels in BALF from both groups of mice (n = 5 per group). DISCUSSION For bronchiectasis, one of the main challenges in studying the interaction between the host and colonizing bacteria is selecting an appropriate animal model to address disease‐related questions. Animal models are indispensable for transforming fundamental scientific discoveries into clinical practice. 14 To enhance the clinical relevance of animal models, scientists focused on simulating the pathological features of pathogens within the host to increase their similarity to human diseases. 15 This was a crucial aspect in the development of the disease models, as the behavior of pathogens within the host directly influences the host's immune response and its reaction to clinical interventions. 7 In this study, we developed an innovative animal model aimed at mimicking P. aeruginosa airway infection in bronchiectasis, with the aim of replicating the pulmonary pathological features of the disease more accurately. In the past, there was no suitable animal model for bronchiectasis. Researchers typically employed CPA airway infection models, which primarily focused on the pathological processes of chronic airway infection and inflammation but lacked the characteristic of bronchiectasis‐like radiological phenotype, thus limiting research on the underlying mechanisms of bronchiectasis and the development of novel therapeutic interventions. This study was the first to develop an animal model capable of reproducing the pulmonary pathological features of human bronchiectasis using the “CPA‐loaded agar beads and papain”–driven approach. The addition of papain not only reduced the mortality rate of the mice but also caused structural changes in the airways (Figure S4). Papain was primarily used to model emphysema in rats. 16 Given the differences in pulmonary pathology between emphysema and bronchiectasis, we continuously refined our model protocol by reducing the concentration of papain to minimize its penetration into the alveoli and subsequent alveolar damage. Besides, preexisting airway pathology alters protease distribution. In our model, CPA‐loaded agar beads were instilled before papain, inducing localized infectious and inflammatory foci predominantly around bronchi. Additionally, to enhance infection efficiency when constructing the animal model with CPA‐coated agar beads, mice were temporarily suspended. Conversely, after papain stimulation, mice were immediately placed in a prone position to reduce the delivery of papain to the distal airways and the resultant changes in alveolar structure, all of which, both physically and biochemically, remains largely confined to the proximal airways in terms of papain activity. Micro‐CT imaging and hispathological analysis of the model showed mild emphysema‐like changes. After 28 days of modeling, micro‐CT scans showed typical bronchiectasis‐like radiological features in both lungs of the mouse model, including an airway‐to‐artery diameter ratio (either inner or outer) ≥1.0, the absence of airway tapering, and visible airways in the periphery of the lungs. These meet the criteria for the radiological diagnosis of adult bronchiectasis as defined by current international guidelines. 13 Therefore, the 28‐day modeling protocol was selected as the optimal timeline for inducing bronchiectasis. Furthermore, in the bronchiectasis mouse model, the integrity of the lung barrier was compromised, and significant infiltration of various immune cells was observed, as evidenced by histopathological analysis. The proportion of neutrophils and eosinophils significantly increased, which ultimately led to excessive mucous secretion in the airways. 11 , 17 This impairment was confirmed by PAS staining, which showed an increase in PAS‐positive cells, further validating the strong potential of this animal model to replicate bronchiectasis. CPA airway infection led to sustained immune responses in the host, particularly those mediated by innate immune cells. 18 Our animal model demonstrated a neutrophil increase in the bronchiectasis group, along with a decrease in AMs and a trend toward an increase in eosinophils. In bronchiectasis, heightened concentrations of pro‐inflammatory mediators and neutrophil serine proteases promote the recruitment of neutrophils to the airways. 19 Besides, eosinophils are recognized for their pro‐inflammatory activity and their role in promoting airway remodeling and injury. 20 These aligned with the typical neutrophil‐driven airway inflammation observed in our model, as well as the increased eosinophils. Alveolar macrophages (AMs) or interstitial macrophages consist of subpopulations with distinct transcriptional profiles that either promote or suppress inflammation in a highly regulated and coordinated manner. 21 AMs often undergo cell death upon pathogen exposure, and the fragments produced due to their death could activate multiple immune cell types, thus initiating a feedforward amplification of the inflammation response. 22 , 23 Interestingly, in the bronchiectasis mouse model, NK cells substantially increase in proportion. NK cells circulate innate lymphocytes that play important roles in host defense by directly killing bacteria or infected cells and producing important cytokines. 24 Patients with NK cell deficiencies are more prone to invasive bacterial infection, bacterial sepsis, and bacterial pneumonia. 25 Furthermore, NK cells could promote neutrophil survival and function as essential mediators linking innate and adaptive immunity during lung infection. 26 The immune cell alterations in the bronchiectasis mouse model closely resembled the immunological features observed in the lungs of bronchiectasis patients, further confirming the reliability of the animal model. In our study, the mice in the bronchiectasis group exhibited significant weight loss. Bronchiectasis patients may present with underweight and/or malnutrition, which impacts lung function, immune function, physical function, and strength. The study showed that being underweight was associated with increased mortality in bronchiectasis. 27 , 28 This aligned with our bronchiectasis animal model. Lung function in bronchiectasis usually leads to an obstructive defect. The mechanisms are not fully known but possibly involve the collapse of large airways, bronchial wall thickening, and mucus retention. 29 Similarly, the pulmonary function tests in our mouse model indicated compromised lung tissue elasticity and compliance, primarily manifested as small airway dysfunction. These findings strongly supported the ability of our mouse model to closely mimic the clinical features of bronchiectasis. Several important limitations should be considered in our study. First, mouse size constrained the spatial resolution of micro‐CT imaging. Second, the use of only female mice may affect the generalizability of findings due to known sex differences in immune responses. Third, we did not directly assess mucociliary clearance function. Finally, repeated anesthesia and tracheal procedures could represent potential confounding factors. Importantly, these acknowledged limitations did not compromise the core radiological or pathological characterization of the model. In future research, extending this work to larger animal models may allow for higher‐resolution imaging and provide an opportunity to address these functional and confirmatory endpoints in a more comprehensive manner. In conclusion, developing animal models that mimic bronchiectasis is challenging, particularly mouse models. Our findings demonstrated the efficacy of the “CPA‐loaded agar beads and papain”–driven approach in establishing a novel mouse model that mimics most of the human bronchiectasis characteristics. We anticipate the model will serve extensively in disease mechanism research and therapeutic assessment. AUTHOR CONTRIBUTIONS Jinfu Xu: Conceptualization; funding acquisition; project administration. Weijun Cao: Conceptualization; project administration. Heng Yang: Formal analysis; investigation; methodology; writing – original draft. Yang Liu: Data curation; formal analysis; methodology; validation; writing – original draft. Yuqing Wang: Methodology; validation; writing – review and editing. Yuhua Wen: Data curation. Yan Chen: Data curation. Rui Fan: Resources; writing – review and editing. Jiayan Xu: Resources; writing – review and editing. Shunlian Hu: Methodology. Hao Qian: Methodology. Rui Jiang: Methodology. FUNDING INFORMATION This work was supported by the Noncommunicable Chronic Diseases‐National Science and Technology Major Project (2024ZD0522400), the National Natural Science Foundation of China (81925001, 82330070), the Innovation Program of Shanghai Municipal Education Commission (202101070007‐E00097), the Program of the Shanghai Municipal Science and Technology Commission (21DZ2201800); the Program of the Shanghai Shenkang Development Center (SHDC12023110), and the Major Project of Guangzhou National Laboratory (Grant no. GZNL2024A02003). CONFLICT OF INTEREST STATEMENT All authors declare no conflict of interest that may directly or indirectly influence the content of the manuscript submitted. ETHICS STATEMENT All animal experiments were approved by the Institutional Animal Care and Use Committee of Tongji University (TJBE00122105). PATIENT CONSENT STATEMENT This study did not involve human participants. PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES No permissions are required. All content is original. CLINICAL TRIAL REGISTRATION This study did not involve clinical trial. Supporting information Appendix S1. Figure S1: CPA‐loaded agar beads induce mild peribronchial inflammation without typical bronchiectasis‐like lesions. (A) Schematic diagram of the CPA‐loaded agar beads alone model. (B) Mice treated with CPA‑loaded agar beads alone for 28 days showed no typical bronchiectasis‑like lesions. Figure S2: Dynamic imaging reveals day 28 as the optimal time point for bronchiectasis modeling in mice. (A) Schematic timeline of the modeling protocol. Lung CT scans were performed on days 14, 28, and 35 post‐induction to evaluate bronchial dilation. (B) Representative lung CT images from control and model mice at day 14, day 28, and day 35. Red arrows indicate typical “hard ring” signs of bronchiectasis. (C) Quantification of the number of typical bronchiectasis signs across groups. Figure S3: Hematoxylin and eosin staining of lung tissue sections from day 14 post‐modeling. H&E staining of lung tissue from control mice and day 14 group, displaying substantial interindividual variability in the extent of lung pathology at day 14 post‐induction. Figure S4: Survival of mice during the 28‐day modeling period. Survival curves of mice subjected to CPA‐only treatment (blue line, n = 10) and the bronchiectasis model (red line, n = 10) over a 28‐day period. Figure S5: FACS gating strategy for identification of myeloid cell in mouse lung single cell suspension. Mouse lung single‐cell‐suspensions were harvested and stained with fixable viability stain to exclude dead cells. Live CD45+ leukocytes were gated, and myeloid cell subsets were identified as follows: neutrophils (CD45̅CD11b̅Ly‐6G̅), alveolar macrophages (CD45̅CD64̅SiglecF̅), interstitial macrophages (CD45̅CD64̅SiglecF−), eosinophils (CD45̅CD64−CD11c−CD11b̅SiglecF̅), and conventional dendritic cells (CD45̅CD64−CD11c̅MHCII̅). Figure S6: FACS gating strategy for identification of lymphoid cell in mouse lung single cell suspension. Mouse lung single‐cell‐suspensions were harvested and stained with fixable viability stain to exclude dead cells. CD45̅ leukocytes were identified, and major lymphoid populations were gated as follows: plasmacytoid dendritic cells (pDCs) as CD45̅B220̅PDCA̅; natural killer (NK) cells as CD45̅CD3−NK1.1̅; T‐helper cells as CD45̅CD3̅CD4̅; cytotoxic T cells as CD45̅CD3̅CD8̅; and B cells as CD45̅PDCA−B220̅. ACKNOWLEDGMENTS We sincerely thank Professor Hexige Saiyin for his invaluable contributions and technical support with micro‐CT imaging. Yang H, Liu Y, Wang Y, et al. A novel mouse model of chronic Pseudomonas aeruginosa infection inducing bronchiectasis‐like phenotype. Anim Models Exp Med. 2026;9:1409‐1419. doi: 10.1002/ame2.70245 Heng Yang, Yang Liu, and Yuqing Wang have contributed equally to this work. Contributor Information Weijun Cao, Email: weijuncao@126.com. Jinfu Xu, Email: jfxucn@163.com. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES Associated Data Supplementary Materials Appendix S1. Figure S1: CPA‐loaded agar beads induce mild peribronchial inflammation without typical bronchiectasis‐like lesions. (A) Schematic diagram of the CPA‐loaded agar beads alone model. (B) Mice treated with CPA‑loaded agar beads alone for 28 days showed no typical bronchiectasis‑like lesions. Figure S2: Dynamic imaging reveals day 28 as the optimal time point for bronchiectasis modeling in mice. (A) Schematic timeline of the modeling protocol. Lung CT scans were performed on days 14, 28, and 35 post‐induction to evaluate bronchial dilation. (B) Representative lung CT images from control and model mice at day 14, day 28, and day 35. Red arrows indicate typical “hard ring” signs of bronchiectasis. (C) Quantification of the number of typical bronchiectasis signs across groups. Figure S3: Hematoxylin and eosin staining of lung tissue sections from day 14 post‐modeling. H&E staining of lung tissue from control mice and day 14 group, displaying substantial interindividual variability in the extent of lung pathology at day 14 post‐induction. Figure S4: Survival of mice during the 28‐day modeling period. Survival curves of mice subjected to CPA‐only treatment (blue line, n = 10) and the bronchiectasis model (red line, n = 10) over a 28‐day period. Figure S5: FACS gating strategy for identification of myeloid cell in mouse lung single cell suspension. Mouse lung single‐cell‐suspensions were harvested and stained with fixable viability stain to exclude dead cells. Live CD45+ leukocytes were gated, and myeloid cell subsets were identified as follows: neutrophils (CD45̅CD11b̅Ly‐6G̅), alveolar macrophages (CD45̅CD64̅SiglecF̅), interstitial macrophages (CD45̅CD64̅SiglecF−), eosinophils (CD45̅CD64−CD11c−CD11b̅SiglecF̅), and conventional dendritic cells (CD45̅CD64−CD11c̅MHCII̅). Figure S6: FACS gating strategy for identification of lymphoid cell in mouse lung single cell suspension. Mouse lung single‐cell‐suspensions were harvested and stained with fixable viability stain to exclude dead cells. CD45̅ leukocytes were identified, and major lymphoid populations were gated as follows: plasmacytoid dendritic cells (pDCs) as CD45̅B220̅PDCA̅; natural killer (NK) cells as CD45̅CD3−NK1.1̅; T‐helper cells as CD45̅CD3̅CD4̅; cytotoxic T cells as CD45̅CD3̅CD8̅; and B cells as CD45̅PDCA−B220̅. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.